CLINICAL PROFILES AND PHYLOGENETIC ANALYSIS OF HIV-1 IN NEWLY DIAGNOSED PATIENTS FROM PUNJAB, PAKISTAN
Main Article Content
Keywords
HIV, Clinical Profiles, Biochemical Markers, Hematological Analysis, Genetic Variations, GP-120, Viral Load
Abstract
This study explored the clinical profiles, and phylogenetically analysis of HIV-1 positive patients compared to a control group. The hematological analysis revealed significantly lower hemoglobin (HB) levels in HIV-1 positive individuals (11.31±0.63 g/dL) compared to the control group (11.84±0.57 g/dL). White blood cell counts (WBCs) were also notably reduced in HIV-1 positive patients (6.52±2.01x10³mm³) compared to the control group (7.85±0.88 x10³mm³), with reference values ranging from 4-11 x10³mm³. Platelet counts (PLTs) exhibited a significant decrease in HIV-1 positive patients (179.21±27.24 x10³mm³) compared to the control group (307.03±36.21 x10³mm³). Biochemical analysis indicated elevated levels of liver enzymes in HIV-1 positive patients, with ALT levels at (63.3±12.3 U/L), AST levels at (52.7±9.5 U/L). Additionally, renal function markers demonstrated increased levels in HIV-1 positive patients, including urea at 41.1±7.4 mg/dL and creatinine at 1.7±0.3 mg/dL compared to the control group. Furthermore, RNA analysis via 1% TAE agarose gel electrophoresis revealed distinctive bands in high viral load samples, providing insights into the quality and integrity of extracted RNA. The electrophoretic separation of three Fragments (F1, F2, and F3) of the surface glycoprotein GP-120 of Human Immunodeficiency Virus type 1 (HIV-1) was visually represented through 1.5% TBE agarose gel electrophoresis. The graphical representations facilitated the analysis of specific characteristics of GP-120 across various samples, contributing to a comprehensive understanding of the viral genetic variations. This integrative approach, combining hematological, biochemical, and genetic analyses, offered a comprehensive perspective on the clinical and molecular aspects of HIV infection, providing valuable insights for further research and potential therapeutic interventions.
References
2. Vizcarra P, Pérez-Elías MJ, Quereda C, Moreno A, Vivancos MJ, Dronda F, et al. Description of COVID-19 in HIV-infected individuals: a single-centre, prospective cohort. The lancet HIV. 2020;7(8):e554-e64.
3. Del Amo J, Polo R, Moreno S, Díaz A, Martínez E, Arribas JR, et al. Incidence and severity of COVID-19 in HIV-positive persons receiving antiretroviral therapy: a cohort study. Annals of internal medicine. 2020;173(7):536-41.
4. Hayes RJ, Donnell D, Floyd S, Mandla N, Bwalya J, Sabapathy K, et al. Effect of universal testing and treatment on HIV incidence—HPTN 071 (PopART). New England Journal of Medicine. 2019;381(3):207-18.
5. Ssentongo P, Heilbrunn ES, Ssentongo AE, Advani S, Chinchilli VM, Nunez JJ, et al. Epidemiology and outcomes of COVID-19 in HIV-infected individuals: a systematic review and meta-analysis. Scientific reports. 2021;11(1):6283.
6. Fleming J, Mathews WC, Rutstein RM, Aberg J, Somboonwit C, Cheever LW, et al. Low-level viremia and virologic failure in persons with HIV infection treated with antiretroviral therapy. Aids. 2019;33(13):2005-12.
7. Al-Mughales JA. Development and Validation of a Three-Parameter Scoring System for Monitoring HIV/AIDS Patients in Low-Resource Settings Using Hematological Parameters. HIV/AIDS-Research and Palliative Care. 2023:599-610.
8. Coco-Bassey SB, Asemota EA, Okoroiwu HU, Etura JE, Efiong EE, Inyang IJ, et al. Glutathione, glutathione peroxidase and some hematological parameters of HIV-seropositive subjects attending clinic in University of Calabar teaching hospital, Calabar, Nigeria. BMC Infectious Diseases. 2019;19(1):1-10.
9. Aziz N, Quint JJ, Breen EC, Oishi J, Jamieson BD, Martinez-Maza O, et al. 30-year longitudinal study of hematological parameters of HIV-1 negative men participating in Los Angeles multicenter AIDS cohort study (MACS). Laboratory medicine. 2019;50(1):64-72.
10. Metry A, Bhaskar J. A study on correlation between blood parameters and CD4 count in people living with HIV/AIDS.
11. Thongsahuan S, Fonghoi L, Kaewfai S, Srinoun K. Precision and accuracy of the Mindray BC‐5000Vet hematology analyzer for canine and feline blood. Veterinary Clinical Pathology. 2020;49(2):207-16.
12. Kumar V, Banala AK, Garcia EG, Cao J, Keck TM, Bonifazi A, et al. SUPPORTING DATA EXPERIMENTAL METHODS 1. Chemistry.
13. Patel P, Rose CE, Collins PY, Nuche-Berenguer B, Sahasrabuddhe VV, Peprah E, et al. Noncommunicable diseases among HIV-infected persons in low-income and middle-income countries: a systematic review and meta-analysis. AIDS (London, England). 2018;32(Suppl 1):S5.
14. Wang H, Wolock TM, Carter A, Nguyen G, Kyu HH, Gakidou E, et al. Estimates of global, regional, and national incidence, prevalence, and mortality of HIV, 1980–2015: the Global Burden of Disease Study 2015. The lancet HIV. 2016;3(8):e361-e87.
15. Control CfD, HIV/AIDS. CfIDDo, HIV/AIDS. NCfIDDo. HIV/AIDS Surveillance: US Department of Health and Human Services, Public Health Service, Centers …; 1990.
16. Grinspoon SK, Fitch KV, Zanni MV, Fichtenbaum CJ, Umbleja T, Aberg JA, et al. Pitavastatin to prevent cardiovascular disease in HIV infection. New England Journal of Medicine. 2023;389(8):687-99.
17. Yeo JY, Goh G-R, Su CT-T, Gan SK-E. The determination of HIV-1 RT mutation rate, its possible allosteric effects, and its implications on drug resistance. Viruses. 2020;12(3):297.
18. Domingo E, García-Crespo C, Lobo-Vega R, Perales C. Mutation rates, mutation frequencies, and proofreading-repair activities in RNA virus genetics. Viruses. 2021;13(9):1882.